Literature DB >> 28629544

Continued Response to One Dose of Nivolumab Complicated by Myasthenic Crisis and Myositis.

Ryan Ying Cong Tan1, Chee Keong Toh2, Angela Takano3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28629544     DOI： 10.1016/j.jtho.2017.02.024

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  11 in total

Review 1.  Neurologic Immune-Related Adverse Events Associated with Immune Checkpoint Inhibition.

Authors:  Peter Chei-Way Pan; Aya Haggiagi
Journal:  Curr Oncol Rep       Date:  2019-11-27       Impact factor: 5.075

Review 2.  Neuromuscular Complications of Programmed Cell Death-1 (PD-1) Inhibitors.

Authors:  Justin C Kao; Adipong Brickshawana; Teerin Liewluck
Journal:  Curr Neurol Neurosci Rep       Date:  2018-08-04       Impact factor: 5.081

Review 3.  Musculoskeletal and Rheumatic Diseases Induced by Immune Checkpoint Inhibitors: A Review of the Literature.

Authors:  Devis Benfaremo; Lucia Manfredi; Michele Maria Luchetti; Armando Gabrielli
Journal:  Curr Drug Saf       Date:  2018

4.  Management of rheumatic complications of ICI therapy: a rheumatology viewpoint.

Authors:  Jan Leipe; Xavier Mariette
Journal:  Rheumatology (Oxford)       Date:  2019-12-01       Impact factor: 7.580

Review 5.  Neuro-ophthalmic Complications of Immune Checkpoint Inhibitors: A Systematic Review.

Authors:  Caberry W Yu; Matthew Yau; Natalie Mezey; Ishraq Joarder; Jonathan A Micieli
Journal:  Eye Brain       Date:  2020-11-03

6.  A single dose of pembrolizumab treatment causing a profound and durable response in lung cancer.

Authors:  Yoshihiro Kondo; Michihiro Kunishige; Naoki Kadota; Yoshio Okano; Hisanori Machida; Nobuo Hatakeyama; Keishi Naruse; Tsutomu Shinohara; Eiji Takeuchi
Journal:  Thorac Cancer       Date:  2022-01-12       Impact factor: 3.500

Review 7.  [Prevalence and treatment of rheumatological adverse events due to immune checkpoint inhibitor therapy].

Authors:  S H Verspohl; H Schulze-Koops; A Heine; V S Schäfer
Journal:  Z Rheumatol       Date:  2020-10       Impact factor: 1.372

8.  Immune checkpoint inhibitors in the onset of myasthenia gravis with hyperCKemia.

Authors:  Koutaro Takamatsu; Shunya Nakane; Shigeaki Suzuki; Takayuki Kosaka; Satoshi Fukushima; Toshihiro Kimura; Azusa Miyashita; Akihiro Mukaino; Shiori Yamakawa; Keisuke Watanabe; Masatoshi Jinnin; Yoshihiro Komohara; Hironobu Ihn; Yukio Ando
Journal:  Ann Clin Transl Neurol       Date:  2018-09-23       Impact factor: 4.511

9.  Camrelizumab-Related Myocarditis and Myositis With Myasthenia Gravis: A Case Report and Literature Review.

Authors:  Jing Bai; Dan Li; Peidan Yang; Kunyan Xu; Yingnan Wang; Qian Li; Jiang Liu; Wenli Du; Fengbin Zhang; Rui Feng
Journal:  Front Oncol       Date:  2022-01-03       Impact factor: 6.244

10.  [Myofasciitis under nivolumab treatment].

Authors:  M Krusche; U Schneider; C Geisler; S Keller; W Stenzel; S Ohrndorf
Journal:  Z Rheumatol       Date:  2021-04-22       Impact factor: 1.372
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.